Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 65 peer-reviewed journal articles Updated
Neurology

The Friedreich Ataxia Guide: Understanding Your Diagnosis

At a Glance

Friedreich Ataxia (FRDA) is a rare, progressive genetic disorder caused by a mutation in the FXN gene. While there is no cure, proactive multidisciplinary care and FDA-approved treatments like omaveloxolone (Skyclarys) can help slow disease progression and improve quality of life.

Receiving a diagnosis of Friedreich Ataxia (FRDA) can feel overwhelming and isolating, but you are now part of a global community dedicated to managing and treating this condition. While FRDA is a progressive (gradually changing over time) multisystem disorder, understanding the science behind it can provide a sense of control and a roadmap for the future [1][2]. Organizations like the Friedreich’s Ataxia Research Alliance (FARA) offer robust patient advocacy and community support [3].

Please explore the pages below to learn more about the biology of the disease, how symptoms evolve, treatment strategies, and what to expect over the long term.

01

Biology & Diagnosis: The Genetics of Friedreich Ataxia

Learn the genetics behind Friedreich Ataxia (FRDA). Understand the FXN gene, GAA repeats, and how to read your genetic lab report for an accurate diagnosis.

02

Symptoms & Multisystem Impact of Friedreich Ataxia

Learn about the multisystem symptoms of Friedreich Ataxia (FRDA), including neurological, cardiac, and musculoskeletal impacts, and how they progress over time.

03

Treatment & Care Team: Managing Friedreich Ataxia

Learn about Friedreich Ataxia (FRDA) treatments, including the FDA-approved medication Skyclarys. Understand how to build your multidisciplinary care team.

04

Prognosis & Long-Term Surveillance in Friedreich Ataxia

Learn about Friedreich Ataxia (FRDA) prognosis and long-term surveillance. Understand the mFARS scale, cardiac monitoring, and managing your scanxiety.

The Science of FRDA

Friedreich Ataxia is a genetic condition caused by a specific change in the FXN gene. Most people with FRDA have an unusual “stutter” in their DNA called a GAA triplet repeat expansion [4]. This genetic glitch prevents the body from making enough of a protein called frataxin [1].

Frataxin acts like a battery technician for your cells. It helps the mitochondria (the powerhouses of the cell) function properly by managing iron and energy production [4][5]. When frataxin levels are low, cells—particularly those in the nervous system and the heart—don’t get the energy they need and can become damaged over time [1][6].

Why It Feels Rare

If you feel like you’ve never heard of this condition before, there is a reason: FRDA is a rare disease. It is the most common inherited ataxia among people of European descent, yet it still only affects a small portion of the population [7]. Prevalence varies by region, but it is estimated to affect roughly 1 in 50,000 people in many areas [8]. Because it is a recessive condition, a person must inherit a modified gene from both parents to develop the disease [1].

Understanding the Timeline

The journey with FRDA is unique for every individual, but researchers have identified common patterns:

  • Typical Onset: The clinical definition for typical onset is before age 25. However, symptoms most frequently begin in childhood or adolescence, often before age 15 [9][10]. “Late-onset” cases can be diagnosed well into adulthood [11].
  • Progression: The disease is progressive, meaning symptoms like balance issues (ataxia), muscle weakness, and fatigue change over time [2].
  • Key Indicators: The number of GAA repeats in your genetic test often correlates with the age of onset and how quickly symptoms may progress [12].

Three Stabilizing Facts for Families

  1. You Are Not Alone in Research: There is a massive, coordinated global effort working specifically on treatments, gene therapies, and “frataxin-boosting” strategies [3][13]. FARA (Friedreich’s Ataxia Research Alliance) provides support and research updates.
  2. FDA-Approved Treatment Exists: For the first time in history, there is an approved pharmacological treatment. Omaveloxolone (Skyclarys) has been approved for adults and adolescents aged 16 and older to slow the progression of the disease [14][15]. While this leaves a gap for younger patients, clinical trials for children under 16 are actively ongoing [16].
  3. Proactive Management Works: While there is no cure yet, a multidisciplinary care approach—involving neurologists, cardiologists, and physical therapists—has been shown to improve quality of life and extend lifespans [17][18].

Immediate Next Steps

After a diagnosis, your medical team will likely focus on gathering “baseline” information to track your health over time:

  • Cardiac Screening: Because low frataxin can affect the heart muscle (cardiomyopathy), an EKG and echocardiogram are essential early steps [6][19].
  • Neurological Baseline: Doctors use tools like the mFARS (modified Friedreich Ataxia Rating Scale) to measure current mobility and coordination [15][20].
  • Physical Therapy: Starting a rehabilitation program early can help maintain independence and function for as long as possible [21][22].
  • Monitoring Blood Sugar: Since FRDA can affect the pancreas, regular checks for diabetes are often recommended [23].

Common questions in this guide

What causes Friedreich Ataxia?
Friedreich Ataxia is caused by a genetic mutation in the FXN gene, usually an unusual repetition of DNA called a GAA triplet repeat expansion. This genetic change prevents the body from making enough of a protein called frataxin, which cells need for proper energy production.
What does the number of GAA repeats mean on my genetic test?
The number of GAA repeats on your genetic test can provide important clues about your condition. Generally, a higher number of repeats correlates with an earlier age of onset and how quickly symptoms may progress over time.
Are there any approved treatments for Friedreich Ataxia?
Yes, there is currently one FDA-approved medication called omaveloxolone (Skyclarys). It is approved for adults and adolescents aged 16 and older to help slow the progression of the disease, while clinical trials for younger children are actively ongoing.
What kind of doctors should be on my care team?
Because Friedreich Ataxia affects multiple body systems, a multidisciplinary care team is best. Your team will typically include a neurologist, a cardiologist to monitor your heart health, and a physical therapist to help maintain mobility and independence.
Why do I need a heart screening after a Friedreich Ataxia diagnosis?
The low levels of frataxin protein associated with the condition can damage heart muscle cells, leading to a condition called cardiomyopathy. Early screenings like an EKG and echocardiogram help establish a baseline to monitor and manage your heart health proactively.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the exact results of the genetic test, specifically the number of GAA repeats on each allele?
  2. 2.Based on the current age and symptoms, what should we expect regarding the rate of progression?
  3. 3.When should we schedule the first baseline cardiac evaluation (EKG and echocardiogram)?
  4. 4.Is the patient a candidate for Skyclarys (omaveloxolone), and if not now, at what age or trial phase can we reconsider?
  5. 5.Can you recommend a multidisciplinary care team or a Friedreich Ataxia Center of Excellence?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Therapeutic Prospects for Friedreich's Ataxia.

    Zhang S, Napierala M, Napierala JS

    Trends in pharmacological sciences 2019; (40(4)):229-233 doi:10.1016/j.tips.2019.02.001.

    PMID: 30905359
  2. 2

    Nonataxia symptoms in Friedreich Ataxia: Report from the Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS).

    Reetz K, Dogan I, Hohenfeld C, et al.

    Neurology 2018; (91(10)):e917-e930 doi:10.1212/WNL.0000000000006121.

    PMID: 30097477
  3. 3

    A global perspective on research advances and future challenges in Friedreich ataxia.

    Indelicato E, Delatycki MB, Farmer J, et al.

    Nature reviews. Neurology 2025; (21(4)):204-215 doi:10.1038/s41582-025-01065-y.

    PMID: 40032987
  4. 4

    Friedreich Ataxia: From the Eye of a Molecular Biologist.

    Muthuswamy S, Agarwal S

    The neurologist 2015; (20(3)):51-5 doi:10.1097/NRL.0000000000000054.

    PMID: 26375377
  5. 5

    Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia.

    Johnson J, Mercado-Ayón E, Clark E, et al.

    Pharmacology research & perspectives 2021; (9(3)):e00755 doi:10.1002/prp2.755.

    PMID: 33951329
  6. 6

    Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study.

    Legrand L, Weinsaft JW, Pousset F, et al.

    Archives of cardiovascular diseases 2022; (115(1)):17-28 doi:10.1016/j.acvd.2021.10.010.

    PMID: 34920960
  7. 7

    Friedreich's Ataxia in Colombia: A Population-Based Study of Incidence and Socioeconomic Determinants.

    Correa-Arrieta C, Castellar-Leones S, Ruiz-Ospina E, et al.

    Movement disorders : official journal of the Movement Disorder Society 2025; (40(12)):2782-2791 doi:10.1002/mds.70033.

    PMID: 40970480
  8. 8

    Friedreich ataxia in Norway - an epidemiological, molecular and clinical study.

    Wedding IM, Kroken M, Henriksen SP, et al.

    Orphanet journal of rare diseases 2015; (10()):108 doi:10.1186/s13023-015-0328-4.

    PMID: 26338206
  9. 9

    Predictors of loss of ambulation in Friedreich's ataxia.

    Rummey C, Farmer JM, Lynch DR

    EClinicalMedicine 2020; (18()):100213 doi:10.1016/j.eclinm.2019.11.006.

    PMID: 31938785
  10. 10

    Neurologic outcomes in Friedreich ataxia: Study of a single-site cohort.

    Pandolfo M

    Neurology. Genetics 2020; (6(3)):e415 doi:10.1212/NXG.0000000000000415.

    PMID: 32337342
  11. 11

    Very late-onset Friedreich's ataxia with rapid course mimicking as possible multiple system atrophy cerebellar type.

    Vidhale TA, Gupta HR, Pj R, Gandhi C

    BMJ case reports 2021; (14(7)) doi:10.1136/bcr-2021-242073.

    PMID: 34301694
  12. 12

    Longitudinal analysis of contrast acuity in Friedreich ataxia.

    Hamedani AG, Hauser LA, Perlman S, et al.

    Neurology. Genetics 2018; (4(4)):e250 doi:10.1212/NXG.0000000000000250.

    PMID: 30065952
  13. 13

    Future Prospects of Gene Therapy for Friedreich's Ataxia.

    Ocana-Santero G, Díaz-Nido J, Herranz-Martín S

    International journal of molecular sciences 2021; (22(4)) doi:10.3390/ijms22041815.

    PMID: 33670433
  14. 14

    Friedreich's ataxia-a rare multisystem disease.

    Reetz K, Lischewski SA, Dogan I, et al.

    The Lancet. Neurology 2025; (24(7)):614-624 doi:10.1016/S1474-4422(25)00175-9.

    PMID: 40541211
  15. 15

    Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.

    Lynch DR, Chin MP, Boesch S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2023; (38(2)):313-320 doi:10.1002/mds.29286.

    PMID: 36444905
  16. 16

    Omaveloxolone: First Approval.

    Lee A

    Drugs 2023; (83(8)):725-729 doi:10.1007/s40265-023-01874-9.

    PMID: 37155124
  17. 17

    Friedreich Ataxia.

    Subramony SH, Lynch DR

    Pediatric neurology 2026; (174()):148-154 doi:10.1016/j.pediatrneurol.2025.10.020.

    PMID: 41252802
  18. 18

    Respiratory Function in Friedreich's Ataxia.

    Viana CF, Jaques CS, Bezerra MLE, et al.

    Movement disorders : official journal of the Movement Disorder Society 2026; (41(4)):921-927 doi:10.1002/mds.70162.

    PMID: 41416841
  19. 19

    A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia.

    Pousset F, Legrand L, Monin ML, et al.

    JAMA neurology 2015; (72(11)):1334-41 doi:10.1001/jamaneurol.2015.1855.

    PMID: 26414159
  20. 20

    Determining the Validity of Conducting Rating Scales in Friedreich Ataxia through Video.

    Tai G, Corben LA, Woodcock IR, et al.

    Movement disorders clinical practice 2021; (8(5)):688-693 doi:10.1002/mdc3.13204.

    PMID: 34307740
  21. 21

    Demographic and clinical features and rehabilitation outcomes of patients with Friedreich ataxia: A retrospective study.

    Doğan-Aslan M, Büyükvural-Şen S, Nakipoğlu-Yüzer GF, Özgirgin N

    Turkish journal of physical medicine and rehabilitation 2018; (64(3)):230-238 doi:10.5606/tftrd.2018.2213.

    PMID: 31453516
  22. 22

    Can rehabilitation improve the health and well-being in Friedreich's ataxia: a randomized controlled trial?

    Milne SC, Corben LA, Roberts M, et al.

    Clinical rehabilitation 2018; (32(5)):630-643 doi:10.1177/0269215517736903.

    PMID: 29072092
  23. 23

    Impact of diabetes in the Friedreich ataxia clinical outcome measures study.

    McCormick A, Farmer J, Perlman S, et al.

    Annals of clinical and translational neurology 2017; (4(9)):622-631 doi:10.1002/acn3.439.

    PMID: 28904984

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or multidisciplinary care team about your specific Friedreich Ataxia diagnosis and treatment plan.

Get notified when new evidence is published on Friedreich ataxia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.